Elopag 25 mg (Eltrombopag Olamine) TabletS

Elopag 25 Tablet contains Eltrombopag Olamine, a thrombopoietin receptor agonist that helps stimulate platelet production in the bone marrow. It is prescribed to increase platelet counts in selected patients with thrombocytopenia and related blood disorders under the supervision of a healthcare professional.

Therapeutic Uses:

• Management of chronic immune thrombocytopenia (ITP) in patients with an insufficient response to other treatments.
• Treatment of severe aplastic anemia (SAA) as recommended by a specialist.
• Improvement of platelet counts in eligible patients with thrombocytopenia associated with chronic hepatitis C to support antiviral therapy when appropriate.
• Helps reduce the risk of bleeding related to persistently low platelet levels.
• Supports maintenance of adequate platelet counts for clinically indicated treatment plans.

Active Ingredient:

• Eltrombopag Olamine INN equivalent to Eltrombopag 25 mg

Dosage Form:

• Film-Coated Tablet

Composition:
Each film-coated tablet contains:

• Eltrombopag Olamine INN equivalent to Eltrombopag 25 mg
• Pharmaceutical-grade excipients sufficient to formulate a stable film-coated tablet.

Always use this medicine exactly as prescribed by your healthcare provider. The dosage is individualized based on the patient's condition, platelet count, age, liver function, and response to treatment.

General Administration Guidelines:

• Take once daily, preferably at the same time each day.
• Swallow the tablet whole with water; do not crush, chew, or split unless advised by your doctor.
• It may be taken on an empty stomach or according to your healthcare provider's instructions.
• Avoid taking it together with dairy products, calcium supplements, iron, magnesium, aluminum, zinc, or antacids. Maintain a gap of at least 2 hours before or 4 hours after these products.
• Regular blood tests may be required to monitor platelet counts and liver function during treatment.
• If a dose is missed, take the next scheduled dose at the usual time. Do not take a double dose to make up for a missed tablet.
• Do not stop or change the dose without consulting your healthcare professional.

Note: Dosage recommendations vary depending on the condition being treated (such as chronic ITP, severe aplastic anemia, or hepatitis C–associated thrombocytopenia). Treatment should always be initiated and monitored by a qualified physician.